Literature DB >> 9886366

Alloreactivity as a source of high avidity peptide-specific human CTL.

C Münz1, R Obst, W Osen, S Stevanović, H G Rammensee.   

Abstract

PBL from HLA-A2- or HLA-A3- donors were stimulated with synthetic peptide libraries fitting HLA-A2 or HLA-A3 motifs and presented on HLA-A2- or HLA-A3-expressing TAP- cells. Peptide library-specific allorestricted CTL were found to constitute up to half the alloreactive CTL response and occurred at twofold lower frequency than autologous peptide library-specific CTL. This indicates that positive selection by one particular MHC class I molecule is not absolutely essential for the generation of CTL restricted to the same molecule. However, positive selection increases their frequency. The CTL obtained differed greatly both with respect to peptide dependency and peptide specificity. Determination of the peptide avidity for one representative CTL clone, 10F4, proved that the method described here allows the stimulation of high avidity cytotoxic T cells. This approach involving in vitro stimulation of T cells restricted toward a MHC molecule that was not present during their negative selection might therefore offer the possibility of isolating CTL against self and foreign peptides with varying avidities. Such T cells might indeed be useful for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886366

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Use of tumour-responsive T cells as cancer treatment.

Authors:  Mary L Disis; Helga Bernhard; Elizabeth M Jaffee
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

2.  A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro.

Authors:  Qian Yu; Li Zhang; Lichen Ouyang; Yeli Gong; Zhihui Liang; Guanxin Shen; Xiufang Weng; Xiongwen Wu
Journal:  Immunogenetics       Date:  2012-12-12       Impact factor: 2.846

3.  Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.

Authors:  Sarka Nemeckova; Kamila Alexova-Zurkova; Petr Hainz; Jitka Krystofova; Jana Mackova; Katerina Roubalova; Marketa Stastna-Markova; Milena Vrana; Jan Vydra
Journal:  Curr Oncol       Date:  2022-04-20       Impact factor: 3.109

Review 4.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

5.  The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules.

Authors:  R Obst; N Netuschil; K Klopfer; S Stevanović; H G Rammensee
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

Review 6.  Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.

Authors:  Heather F Jones; Zaki Molvi; Martin G Klatt; Tao Dao; David A Scheinberg
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

7.  MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy.

Authors:  Georg Dössinger; Mario Bunse; Jeannette Bet; Julia Albrecht; Paulina J Paszkiewicz; Bianca Weißbrich; Isabell Schiedewitz; Lynette Henkel; Matthias Schiemann; Michael Neuenhahn; Wolfgang Uckert; Dirk H Busch
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

8.  Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Renate Hagedoorn; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.